BriaCell Therapeutics Corp. Discusses its Plan to Revolutionize Cancer Immunotherapy in Exclusive NetworkNewsWire Audio Interview

NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) — via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) (“BriaCell” or “the Company”), focused on developing a targeted and safe approach to the management of cancer.


The interview can be heard at:


Please also visit BriaCell’s Recent News & Events Page:


NNW’s Stuart Smith introduces BriaCell’s CEO, Dr. Bill Williams in an interview that highlights the Company’s innovative business model, milestones and unique immunotherapeutic approach to cancer treatment.


BriaCell is an immune-oncology company developing the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer. Dr. Williams notes that since the Company’s inception in 2014, it has made excellent progress through successfully conducting clinical trials for its lead immunotherapy candidate, Bria-IMT(Trademarked). BriaCell recently added new clinical sites for conducting its Phase IIa studies, which Dr. Williams says will be beneficial to the recruitment of eligible patients, as well as validation of the Company’s technology by leading academic experts.


Dr. Williams next highlights the strength of BriaCell’s management team, including his own expertise in moving therapies through clinical testing, bench-to-bedside research and drug development. The team also boasts R&D technical and scientific experience, with varied expertise in moving programs forward for developing therapeutics that will fulfill the FDA’s stringent marketing requirements, and become available to the patients who need them the most.


BriaCell has accomplished several milestones in 2018, including obtaining topline safety and efficacy clinical data in its clinical study and advancing BriaCell’s clinical programs. The Company published a comprehensive research paper for Frontiers in Immunology providing details on the mechanism by which its targeted immunotherapy is unique in harnessing the patient’s immune system to specifically attack cancer cells.


Moving forward, BriaCell is focused on several initiatives, including the start of a combination therapy study to further boost the efficacy of its lead candidate, as well as generating its personalized off-the-shelf immunotherapy treatments to cover 90% of patient population, a major focus of the Company, and one Dr. Williams believes is “going to revolutionize cancer immunotherapy.”


The discussion concludes with Dr. Williams attributing BriaCell’s focus on making a positive impact in patient’s lives, some entering the Company’s studies after exhausting all other options, as both rewarding and a key factor of success.


With a strategic path in place, Dr. Williams says, “We’re still, I believe, tremendously undervalued compared to our competitors… So we think that this is a great opportunity for investors to come in to get as excited about our story as we are and to follow us along as we start to change the face of the immuno-oncology space.”


About BriaCell

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer.


BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT(Trademarked), its lead candidate, in patients with advanced breast cancer. This trial is listed in as NCT03066947. Additionally, the FDA recently approved a combination study of Bria-IMT with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in as NCT03328026.


BriaCell is developing Bria-OTS(Trademarked), an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90% of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies.


For additional information on BriaCell, please visit website:


Cautionary Note Regarding Forward-Looking Information

Except for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company’s public filings available at


Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Contact Information

For further information, please contact:
BriaCell Therapeutics Corp.:
Farrah Dean
Manager, Corporate Development
Phone: 1-888-485-6340


About NetworkNewsAudio

NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.


For more information, visit:


Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office


Source: NetworkNewsWire